Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

Dian Wang(Medical College of Wisconsin), Burton Eisenberg(Hoag Memorial Hospital Presbyterian), George D. Demetri(American Society of Clinical Oncology), Charles D. Blanke(SWOG Cancer Research Network), Margaret von Mehren(Temple University Health System), Michael C. Heinrich(VA Portland Health Care System), Qiang Zhang(RTOG Foundation), John M. Kane(Roswell Park Comprehensive Cancer Center), Scott H. Okuno(Mayo Clinic), John P. Hoffman(Fox Chase Cancer Center), James C. Watson(Vanderbilt University)
Annals of Surgical Oncology
December 27, 2011
10.1245/s10434-011-2190-5
Cited by 202

Related Papers

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.1k
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>
|Journal of Clinical Oncology|2008|1k